Gilead Sciences (NasdaqGS:GILD) FY Conference Transcript

Gilead Sciences FY Conference Summary Company Overview - Company: Gilead Sciences (NasdaqGS: GILD) - Event: FY Conference held on March 03, 2026 Key Industry Insights 1. 2026 Guidance - Gilead provided a mid-single digit growth guidance of 4%-5% for its base business in 2026, with an additional 2% impact from ACA and MFN adjustments [13][14] - Specific guidance for the HIV segment indicates a 6% year-over-year growth, primarily driven by the product Biktarvy [13][14] - The HIV prevention franchise, particularly Descovy, is expected to grow significantly, with guidance set at $800 million, up from $150 million in 2025 [14] 2. Product Performance - Biktarvy is recognized as the standard of care for HIV treatment, showing strong performance in both naive and switch patient populations [17][18] - The HIV prevention market is growing at approximately 55%, with expectations for continued growth through 2026 [14][19] - Yescarta, an injectable product, is anticipated to see steady growth, supported by a 90% access rate and a recent DTC campaign aimed at normalizing HIV prevention [21][25][26] 3. Market Dynamics - The overall HIV treatment market is projected to grow at 2-3% annually, with 40% of HIV-positive individuals in the U.S. not currently virologically suppressed [49][50] - Gilead is focusing on lifecycle management and patient-centric options to maintain its market leadership in HIV treatment [20][48] 4. Oncology Developments - Gilead announced the acquisition of Arcellx, which is expected to enhance its oncology portfolio, particularly in the multiple myeloma space, with a market potential of up to $20 billion [55][56] - The company is also preparing for a potential launch of Trodelvy in the first-line setting for breast cancer, following positive data from recent trials [60][61] 5. Inflammation Pipeline - Gilead's inflammation pipeline includes promising products in phase 2 trials, which are not yet fully recognized by investors [85][86] - The company aims to position its inflammation segment as a third pillar alongside its HIV and oncology businesses [85][86] Additional Considerations - Gilead is maintaining a disciplined approach to business development, with ongoing investments in early development deals while managing operational expenses [81][84] - The company is optimistic about its growth trajectory, particularly in the HIV prevention and treatment markets, and is focused on expanding its product offerings and market share [34][48][85]